Match tier
Confirmed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-10-05
M
Meagan B. Myers
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Research Biologist
Also affiliated: United States Food and Drug Administration (2003–2026)
18 h-index
42 pubs
905 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Meagan B. Myers' research focuses on the study of somatic mutations and their role in aging and disease, particularly cancer. Her work investigates the fixation and spread of mutations within adult human tissues, such as the colon, and explores the accumulation of mitochondrial DNA mutations in aging organisms like mice.
Myers has published extensively on advanced sequencing technologies, including error-corrected next-generation sequencing, and their application to genotoxicity testing and cancer risk assessment. Her research also examines specific gene mutations, such as those in PIK3CA, KRAS, HRAS, and BRAF, in the context of breast cancer heterogeneity and personalized treatment strategies. She has collaborated with several researchers at the National Center for Toxicological Research, including Barbara L. Parsons, Robert H. Heflich, Page B. McKinzie, and Kelly L. Harris, on multiple publications.
Her scholarship metrics include an h-index of 20, with 47 total publications and 978 total citations. Myers leads a research group and has been recently active, with her most recent publication in 2026.
Metrics
- h-index: 18
- Publications: 42
- Citations: 905
Positions
-
Research Biologist 2006–presentNational Center for Toxicological Research Division of Genetic and Molecular Toxicology ORCID
Selected Publications
-
Using error-corrected sequencing for evaluating mutagenicity of molnupiravir in humans (2026)
-
Transferability, Reproducibility and Sensitivity of Mutation Quantification by Duplex Sequencing (2025)
-
Evaluating teratoma formation risk of pluripotent stem cell-derived cell therapy products: a consensus recommendation from the Health and Environmental Sciences Institute’s International Cell Therapy Committee (2025)
-
CarcSeq detection of lorcaserin-induced clonal expansion ofPik3caH1047R mutants in rat mammary tissue (2024)
-
Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing ( IWGT ) (2024)
-
Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment (2023)
-
A Brief Practical Guide to PCR (2023)
-
Clinical Applications of Nucleic Acid Amplification (2023)
-
Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing (2023)
-
Assessment of Clonal Expansion Using CarcSeq Measurement of Lung Cancer Driver Mutations and Correlation With Mouse Strain- and Sex-Related Incidence of Spontaneous Lung Neoplasia (2021)
-
Quantification of cancer driver mutations in human breast and lung DNA using targeted, error‐corrected CarcSeq (2020)
-
Outgrowth of erlotinib-resistant subpopulations recapitulated in patient-derived lung tumor spheroids and organoids (2020)
-
ACB-PCR Quantification of Low-Frequency Hotspot Cancer-Driver Mutations (2020)
-
Rationale and Roadmap for Developing Panels of Hotspot Cancer Driver Gene Mutations as Biomarkers of Cancer Risk (2019)
-
Low-Frequency Mutational Heterogeneity of Invasive Ductal Carcinoma Subtypes: Information to Direct Precision Oncology (2019)
Collaboration Network
Top Collaborators
Barbara L. Parsons
National Center for Toxicological Research
31 shared publications
In database
- Fixation and Spread of Somatic Mutations in Adult Human Colonic Epithelium
- Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment
- Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing
- Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas
- Assessment of K-Ras mutant frequency and micronucleus incidence in the mouse duodenum following 90-days of exposure to Cr(VI) in drinking water
Showing 5 of 31 shared publications
Karen L. McKim
National Center for Toxicological Research
20 shared publications
In database
- Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas
- Temporal Changes in K-ras Mutant Fraction in Lung Tissue of Big Blue B6C3F1 Mice Exposed to Ethylene Oxide
- A subset of papillary thyroid carcinomas contain KRAS mutant subpopulations at levels above normal thyroid
- ACB‐PCR measurement of H‐ras codon 61 CAA→CTA mutation provides an early indication of aristolochic acid I carcinogenic effect in tumor target tissues
- Variation in organ‐specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas
Showing 5 of 20 shared publications
Malathi Banda
National Center for Toxicological Research
7 shared publications
In database
- Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas
- Outgrowth of erlotinib-resistant subpopulations recapitulated in patient-derived lung tumor spheroids and organoids
- Ovarian effects of prenatal exposure to benzo[a]pyrene: Roles of embryonic and maternal glutathione status
- Low-Frequency Mutational Heterogeneity of Invasive Ductal Carcinoma Subtypes: Information to Direct Precision Oncology
- ACB-PCR Quantification of Low-Frequency Hotspot Cancer-Driver Mutations
Showing 5 of 7 shared publications
Fanxue Meng
National Center for Toxicological Research (US)
6 shared publications
- Oncomutations as biomarkers of cancer risk
- Low-Frequency Kras Mutations are Prevalent in Lung Adenocarcinomas
- ACB-PCR Quantification of Somatic Oncomutation
- p53 codon 271 CGT to CAT mutant fraction does not increase in nasal respiratory and olfactory epithelia of rats exposed to inhaled naphthalene
- Abstract 3179: ACB-PCR quantification of PIK3CA codon 1047 CAT to CGT mutant fraction in human tumor and non-tumor tissues
Showing 5 of 6 shared publications
Yiying Wang
National Center for Toxicological Research (US)
6 shared publications
- Temporal Changes in K-ras Mutant Fraction in Lung Tissue of Big Blue B6C3F1 Mice Exposed to Ethylene Oxide
- ACB‐PCR measurement of H‐ras codon 61 CAA→CTA mutation provides an early indication of aristolochic acid I carcinogenic effect in tumor target tissues
- p53 codon 271 CGT to CAT mutant fraction does not increase in nasal respiratory and olfactory epithelia of rats exposed to inhaled naphthalene
- Hotspot oncomutations: implications for personalized cancer treatment
- Abstract 1739: The prevalence of KRAS, PIK3CA, and BRAF mutant subpopulations in tumors may be impacting the success of personalized cancer treatment
Showing 5 of 6 shared publications
Page B. McKinzie
National Center for Toxicological Research
6 shared publications
In database
- Oncomutations as biomarkers of cancer risk
- ACB-PCR Quantification of Somatic Oncomutation
- Abstract 1739: The prevalence of KRAS, PIK3CA, and BRAF mutant subpopulations in tumors may be impacting the success of personalized cancer treatment
- A Brief Practical Guide to PCR
- Abstract 3179: ACB-PCR quantification of PIK3CA codon 1047 CAT to CGT mutant fraction in human tumor and non-tumor tissues
Showing 5 of 6 shared publications
Robert H. Heflich
National Center for Toxicological Research
5 shared publications
In database
- Accumulation of point mutations in mitochondrial DNA of aging mice
- Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment
- Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing
- Using ΦX174 DNA as an Exogenous Reference for Measuring Mitochondrial DNA Copy Number
- Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing ( IWGT )
Connie L. Chen
Health and Environmental Sciences Institute (US)
4 shared publications
- Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment
- Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing
- Evaluating teratoma formation risk of pluripotent stem cell-derived cell therapy products: a consensus recommendation from the Health and Environmental Sciences Institute’s International Cell Therapy Committee
- Transferability, Reproducibility and Sensitivity of Mutation Quantification by Duplex Sequencing
Mugimane G. Manjanatha
National Center for Toxicological Research
3 shared publications
In database
- Accumulation of point mutations in mitochondrial DNA of aging mice
- Temporal Changes in K-ras Mutant Fraction in Lung Tissue of Big Blue B6C3F1 Mice Exposed to Ethylene Oxide
- Dose and temporal evaluation of ethylene oxide‐induced mutagenicity in the lungs of male big blue mice following inhalation exposure to carcinogenic concentrations
B. Bhaskar Gollapudi
Michigan Molecular Institute (United States) (US)
3 shared publications
- Temporal Changes in K-ras Mutant Fraction in Lung Tissue of Big Blue B6C3F1 Mice Exposed to Ethylene Oxide
- Dose and temporal evaluation of ethylene oxide‐induced mutagenicity in the lungs of male big blue mice following inhalation exposure to carcinogenic concentrations
- Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing ( IWGT )
Kelly L. Harris
National Center for Toxicological Research
3 shared publications
In database
- Quantification of cancer driver mutations in human breast and lung DNA using targeted, error‐corrected CarcSeq
- Rationale and Roadmap for Developing Panels of Hotspot Cancer Driver Gene Mutations as Biomarkers of Cancer Risk
- Assessment of Clonal Expansion Using CarcSeq Measurement of Lung Cancer Driver Mutations and Correlation With Mouse Strain- and Sex-Related Incidence of Spontaneous Lung Neoplasia
Francesco Marchetti
Health Canada (CA)
3 shared publications
- Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment
- Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing
- Transferability, Reproducibility and Sensitivity of Mutation Quantification by Duplex Sequencing
George R. Douglas
Health Canada (CA)
3 shared publications
- Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment
- Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing
- Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing ( IWGT )
Anthony M. Lynch
Genetic Technologies (Australia) (AU)
3 shared publications
- Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment
- Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing
- Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing ( IWGT )
Jesse J. Salk
Blaze Bioscience (United States) (US)
3 shared publications
- Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment
- Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing
- Transferability, Reproducibility and Sensitivity of Mutation Quantification by Duplex Sequencing
Similar Researchers
Based on overlapping research topics
Page B. McKinzie
National Center for Toxicological Research
Cancer-related molecular mechanisms research
Genomics and Phylogenetic Studies
Pharmacological Effects and Toxicity Studies
Karen L. McKim
National Center for Toxicological Research
Cancer-related molecular mechanisms research
Pharmacological Effects and Toxicity Studies
Disease Models, Animal
Lei Guo
National Center for Toxicological Research
Genomics and Phylogenetic Studies
Pharmacological Effects and Toxicity Studies
Disease Models, Animal
Ji‐Eun Seo
National Center for Toxicological Research
Cancer-related molecular mechanisms research
Pharmacological Effects and Toxicity Studies
Disease Models, Animal
Eleanor R. Schrems
University of Arkansas at Fayetteville
Cancer-related molecular mechanisms research
Genomics and Phylogenetic Studies
Pharmacological Effects and Toxicity Studies
Kelly L. Harris
National Center for Toxicological Research
Cancer-related molecular mechanisms research
Genomics and Phylogenetic Studies
Pharmacological Effects and Toxicity Studies